Dr. Amiot Mathilde | Health Sciences | Best Researcher Award

Dr. Amiot Mathilde | Health Sciences | Best Researcher Award

Dr. Amiot Mathilde, Universite Paris Cite, France

Dr. Mathilde Amiot is a Resident in Dermatology with a specialization in Oncology, based in Paris, France. She holds a Master’s degree in Molecular and Cellular Biology with honors from the University of Paris and completed her medical thesis in 2024 on the topic of “When to Stop Immunotherapy in Advanced Melanoma: Emulation of Target Trials,” earning congratulations from the jury and a Silver Medal. Dr. Amiot ranked 234 in the ECN exam and has gained extensive clinical experience through rotations in dermatology, internal medicine, vascular medicine, medical oncology, and radiotherapy across renowned Parisian hospitals, including Saint-Louis, Ambroise-Paré, Bichat, and Beaujon. She has also completed specialized diplomas in dermoscopy and dermatological manifestations of systemic diseases and contributed to the FDVF Editorial Committee. Dr. Amiot is committed to advancing dermatology and oncology research and patient care.

Professional Profile 🎓

Scopus

Orcid

Summary of Suitability for Best Researcher Award: Mathilde Amiot 🌍

Dr. Mathilde Amiot is a highly promising candidate for the Best Researcher Award, given her academic excellence, clinical experience, and notable contributions to the field of dermatology and oncology. Below are the key aspects supporting her suitability:

Education 📚

  • 2011: Baccalauréat
  • 2012-2013: PACES, University of Paris VII
  • 2016-2017: Master 1 (M1) in Cell Biology, Physiology, and Pathology
  • 2022-2023: Master 2 (M2) in Molecular and Cellular Biology, Biomolecules, Molecular Biology, and Pathology (BBPM), completed with honors
  • 2018-2019: ECN, Paris VII University (Rank 234)
  • 2020-2021: DU in Dermoscopy
  • 2021-2022: DIU in Dermatological Manifestations of Systemic Diseases

Work Experience 💼

  • 1st Semester: Dermatology Department (Pr BAGOT), Hospital Saint Louis
  • 2nd Semester: Internal Medicine Department (Pr HANSLIK), Hospital Ambroise Paré
  • 3rd Semester: Dermatology Department (Pr DESCAMPS), Hospital Bichat
  • 4th Semester: Vascular Medicine Department (Dr PRIOLLET), Hospital Saint Joseph
  • 5th Semester: Medical Oncology Department (Pr CULINE), Hospital Saint Louis
  • 6th Semester:
    • Radiotherapy Department (Pr HENNEQUIN) – 3 months
    • Dermatology Department (Pr BOUAZIZ), Hospital Saint Louis – 3 months
  • 7th Semester: General Dermatology and Oncology Department (Pr FUNCK BRENTANO), Hospital Ambroise Paré
  • 8th Semester: Dermatology Department (Dr LE BOZEC), Hospital Beaujon
  • 9th Semester: Dermatology Department (Pr DESCAMPS), Hospital Bichat

Awards and Recognition 🏅

  • 2024: Silver Medal for Medical Thesis: “When to Stop Immunotherapy in Advanced Melanoma: Emulation of Target Trials” (Chair: Pr. Bouaziz, Directed by Pr. Lebbé)
  • 2023: Editorial Committee Member of FDVF
  • 2022: Recognition for excellence in Clinical Research during M2 Program (BBPM)
  • 2019: Ranked 234 in National Ranking Exam (ECN), demonstrating exceptional academic performance

Research Skills 🔬

  • Clinical Trials Expertise:
    • Design and execution of retrospective and target-emulation studies
    • Data analysis using advanced statistical methods
    • Application of evidence-based medicine in oncology research
  • Technical Proficiency:
    • Dermoscopy techniques for early detection of skin cancers
    • Histopathological analysis and biopsy interpretation
    • Use of molecular biology tools in pathology
  • Software and Data Analysis:
    • Proficient in SPSS, R, and Python for statistical analysis
    • Use of medical imaging tools for dermatological diagnostics
  • Project Management:
    • Coordination of interdisciplinary teams for clinical and academic projects
    • Extensive experience in manuscript preparation and grant writing

Publication Top Notes 📖

When to stop immunotherapy for advanced melanoma: the emulated target trials

THERAPEUTIC REVOLUTIONS AGAINST MELANOMA | Révolutions thérapeutiques contre le mélanome

Successful rechallenge with avelumab in Merkel cell carcinoma